NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain

...atients who have or are suspected to have paralytic ileus. NUCYNTA(TM) is also contraindicated in patients currently using or within 14 days of using monoamine oxidase inhibitors (MAOIs) due to potential additive effects on norepinephrine levels, which may result in adverse cardiovascular events. Respira...

Boys May Feel a Genetic Pull Toward Gangs

...nt street gangs. But a new study finds that the urge to join gangs might lie, at least in part, in their genes. Boys who have a variant of the gene monoamine oxidase A (MAOA) -- otherwise known as the "warrior gene" -- are not only more likely to be in gangs than boys without the variant, but they tend to b...

Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration

...dults 18 and over. Cymbalta is not for everyone. Patients should not take Cymbalta if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine), or have uncontrolled glaucoma. Patients should speak with their doctor about any medi...

Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18

...tivity or idiosyncrasy to sympathomimetic amines; agitated states; glaucoma; a history of drug abuse; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs). Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents...

New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.

...lic compounds (e.g., cyclobenzaprine, promethazine, etc.), or other opioids. Administration of RYZOLT may enhance the seizure risk in patients taking monoamine oxidase (MAO) inhibitors, neuroleptics, or other drugs that reduce the seizure threshold. Risk of convulsions may also be increased in patients with ...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)

...he treatment of major depressive disorder. Savella is not approved for use in pediatric patients. Savella is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) concomitantly or within 14 days of discontinuing treatment with an MAOI or in patients with uncontrolled narrow-angle glauc...

CAMH scientist first psychiatrist to win Royal College Medal Award in Medicine

...no one had ever found a convincing explanation for monoamine loss. In 2006, Dr. Meyer unlocked this mystery and...curs in major depressive episodes the new leading monoamine theory of depression. Dr. Meyer, who also holds...hemistry of Depression, investigated whether brain monoamine oxidase A (MAO-A) an enzyme that breaks down chem...

District Court Decision Received in CONCERTA(R) Patent Case

...RTA; significant anxiety, tension, or agitation; glaucoma; tics, Tourette's syndrome, or family history of Tourette's syndrome; current or past use of monoamine oxidase inhibitor (MAOI); esophagus, stomach, or intestinal narrowing. Children under 6 years of age should not take CONCERTA. Abuse of methylphe...

GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder

...alled sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the doctor bef o re taking V yv a n se if you or your child is being treat...

FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression

...e events in elderly patients with dementia-related psychosis treated with olanzapine, a component of Symbyax. Symbyax should not be used with a monoamine oxidase inhibitor (MAOI) or within at least 14 days of discontinuing an MAOI. At least five weeks should be allowed after stopping Symbyax before star...

Monoamine in Medical Technology

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

...icals Inc., which also licensed the RIMA series of selective and reversible monoamine oxidase inhibitor (MAOI) compounds to CeNeRx. The lead compound in that pr...nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for the treatment of major dep...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

...ents with suspected or confirmed cases of paralytic ileus. NUCYNTA(TM) is also contraindicated in patients currently using or within 14 days of using monoamine oxidase inhibitors (MAOI) due to potential additive effects on norepinephrine levels, which may result in adverse cardiovascular events. Respirat...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

...alled sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the doctor before taking Vyvanse or Adderall XR if you or your child is being treated ...

Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)

...alled sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the doctor before taking Vyvanse if you or your child is being treated for or has sympto...

Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial

...afinamide is believed to have a novel dual mechanism of action based on the enhancement of the dopaminergic function (through reversible inhibition of monoamine oxidase-B [MAO-B] and dopamine uptake) and reduction of glutamatergic activity by inhibiting glutamate release. About Parkinson's disease ...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

...ults 18 and over. Cymbalta is not for everyone. Patients should not take Cymbalta if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine) or have uncontrolled glaucoma. Patients should speak with their doctor about any medic...

Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain

...18 and over. Duloxetine is not for everyone. Patients should not take Duloxetine if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine), or have uncontrolled glaucoma. Patients should speak with their doctor about any medi...

FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain

...ression, acute or severe bronchial asthma or hypercapnia); in patients with paralytic ileus; or in patients currently using or within 14 days of using monoamine oxidase inhibitors (MAOI). Due to its mu-opioid receptor agonism, respiratory depression is a possible adverse event of tapentadol. Tapentad...

CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)

... drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A (MAO-A). The primary objective of this P...agent." Similar to the mechanism of conventional monoamine oxidase A inhibitors (MAOI), the triple-action mec... most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, has entered Phase II development...

CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study

...oping and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, has completed Phase I development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current ag...

Monoamine in Medical Dictionary

Serotonin

... Serotonin (pronounced /ˌsɛrəˈtoʊnən/) is a monoamine neurotransmitter. ... 2.3 Endothelial cell function and Serotonin . 3 Biosynthesis. 4 Drugs targeting the 5 ... serotonin n. An organic c...

Monoamine in Biological News

Genetic marker linked to problem behaviors in adults with developmental disabilities

...injury or property destruction and set out to determine if there was a genetic underpinning for these behaviors. They focused on the gene that encodes monoamine oxidize A or MAOA. MAOA is involved in the regulation of the neurotransmitter serotonin, which is linked to appetite and mood, and the neurotransmitte...

'Neurological work-arounds' offer hope to people with monoamine-related disorders

...tating, life-threatening mutation in the vesicular monoamine transporter gene. This mutation caused their brain cells to be unable to release monoamine neurotransmitters such as serotonin and dopamine. ...to that of humans. And as is the case with humans, monoamine neurotransmitters are considered necessary for the...

Sociological research shows combined impact of genetics, social factors on delinquency

... genetic polymorphisms that predict delinquency include: (1) the 30-base pair (bp) promoter-region with a variable number tandem repeat (VNTR) in the monoamine oxidase A (MAOA) gene, (2) the 40-bp VNTR in the dopamine transporter 1 (DAT1) gene and (3) the Taq1 polymorphism in the dopamine D2 receptor (DRD2) g...

News tips from the Journal of Neuroscience

...r- and anxiety-like behaviors) were present exclusively or were worse in UNG-deficient mice compared to wild type. Other effects (including changes in monoamine levels and decreased adult neurogenesis) were independent of genotype, suggesting that an increased presence of uracil in DNA contributes to some but ...

New test could help consumers avoid surprise headaches from chocolate, wine

...lamine, which have been known to cause nausea, headaches, and respiratory disorders. These toxins can be particularly dangerous in people with reduced monoamine oxidase (MAO) activity or those taking MAO inhibitors, an older class of antidepressant medications, because they can potentially interact and cause d...

Nobelist discovers antidepressant protein in mouse brain

...treatments designed to boost weak serotonin systems on p11 levels in brain cells by administering to mice two types of antidepressants ?a tricyclic, a monoamine oxidase (MAO) inhibitor ?and electroconvulsive therapy (ECT). "These three different ways of treating depression all caused an increase in the amou...

Aggression-related gene weakens brain's impulse control circuits

...see how this gene variant biases the brain toward impulsive, aggressive behavior." The gene is one of two common versions that code for the enzyme monoamine oxydase-A (MAO-A), which breaks down key mood-regulating chemical messengers, most notably serotonin. The previously identified violence-related, or L...

Smoking damages key regulatory enzyme in the lung

...emical that binds to a specific form of the enzyme monoamine oxidase (MAO A) to track MAO A levels in both smok...r Medicine member. In the study, "Comparison of monoamine Oxidase A in Peripheral Organs in Nonsmokers and S...to the practice of health care." "Comparison of monoamine Oxidase A in Peripheral Organs in Nonsmokers and S...

Monoamine in Biological Technology

Neurocrine Biosciences Reports Second Quarter 2009 Results

...e compared to standard-of-care treatment; enrollment of 50 subjects is planned. VMAT2 Update The highly selective blockade of the Vesicular monoamine Transporter 2 (VMAT2) with NBI-98854 should be of clinical benefit in patients with a variety of CNS diseases, especially those with involuntary hyper...

Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

...alled sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the doctor before taking Vyvanse if you or your child is being treated for or has ...

Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment

...alled sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the doctor before taking Vyvanse if you or your child is being treated for or has symp...

Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity

...ramadol, methadone, propoxyphene, dextromethorphan, St. John's wort, mirtazapine, or cyclobenzaprine. Patients should not take AZILECT with other monoamine oxidase inhibitors (MAOIs), amphetamines, cold remedies containing decongestants and weight-reducing preparations containing pseudoephedrine, phenylep...

FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD

...alled sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the doctor before taking Vyvanse if you or your child is being treated for or has symp...

Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder

...an Inc. (Nasdaq: MYL ), today announced that it has begun to market and distribute EMSAM(R) in the U.S. EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor (MAOI), which was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of major depressive disorder. ...

Neurocrine Biosciences Reports First Quarter 2009 Results

...fety, tolerability and efficacy of UCN2 in this group. Initiation of this trial is expected in mid-2009 pending regulatory approval. Vesicular monoamine Transporter 2 Inhibitor (VMAT2 ) VMAT2 is a protein concentrated in the human brain that is essential for the transmission of nerve impulses...

CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors

...ping and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current agents f...

Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD

...alled sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the doctor before taking VYVANSE if you or your child is being treated for or has sympto...

New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinson's Disease Drug Development

...factors (human fetal implants, GDNF, neurturin, neublastin, GAD/glutamic acid decarboxylase), alpha-synuclein; -- Dopamine agonists, monoamine oxidase inhibitors; -- Levodopa formulations, COMT inhibitors; and -- Adenosine A2A receptor antagonists, cholinesterase inhibitors, AMPA, ...

Monoamine in Biological Products

Anti-Vesicular Monoamine Transporter 2 (VMAT2) Polyclonal Antibody, Unconjugated from CHEMICON

Description: Vesicular Monoamine Transporter 2 (VMAT2). An antibody made to the C-terminal VMAT2 peptide detected a major band at ~55 kDa in postnuclear supernatants of CHO transfected with VMAT2 and not in wild type cells (2). Some additional bands, both higher and lower molecular weight, were also detected an...
Company:CHEMICON

Monoamine in Biological Definition

Enzyme

...two molecules with a covalent bond Lyases : all those enzymes that can eliminate a group from a molecule to form a double bond and vice versa. monoamine oxidase (MAO): oxidize certain neurotransmitters and biologically active amines NADH dehydrogenase : the first complex in the electron transfer...

Neurotransmitter

...nts the conversion of tyrosine to L-DOPA , the precursor to dopamine; reserpine prevents dopamine storage within vesicles; and deprenyl inhibits monoamine oxidase (MAO) B and thus increases dopamine levels. Diseases may affect specific neurotransmitter pathways. For example, Parkinson's disease is a...

Selective serotonin reuptake inhibitor

...ocess, the other 90% are released from the receptors and taken up again by monoamine transporters in the sending cell (thus reuptake ). Depression has bee...le for serotonin, as opposed to earlier antidepressants, which affect other monoamine neurotransmitters as well. Because of this, SSRIs lack some of the side ef...

Monoamine in Biological Dictionary

Epinephrine

...transmitter that participates in the "fight or flight" response of the sympathetic nervous system. It is a catecholamine, a sympathomimetic monoamine produced by the adrenal glands from the... epinephrine also epinephrin n. A hormone secreted by the adrenal medulla that is released into t...